Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BloodiNO: Nitric Oxide in Cardiac Surgery Transfusion
NCT02217683Phase 2Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- Mar 2016
- Primary completion
- Dec 2016
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 1
01
Overview
Phase 2, randomised trial of nitric oxide in pulmonary hypertension (PH) (3 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Pulmonary vascular resistance index at 6 hours. Planned start Mar 2016; status: withdrawn.
02
Drugs
nitric oxide
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT02217683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02217683.